Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.
Qyuns Therapeutics Co., Ltd. has received approval from the Human Research Ethics Committee in Australia for a Phase I clinical trial of its bispecific antibody, QX030N/CLD-423, marking a significant milestone in its international clinical development efforts. This approval, accompanied by a $5 million milestone payment from its partner Caldera Therapeutics, underscores the company’s strategic positioning in the field of autoimmune and allergic diseases and highlights its potential for future financial gains through additional milestone payments and royalties.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a company based in China that operates in the biotechnology industry, focusing on the development of bispecific antibodies for autoimmune and allergic diseases. The company collaborates with global partners to advance its products in international markets.
Average Trading Volume: 694,331
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.76B
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.